LONDON, UNITED KINGDOM--(Marketwired - Nov 18, 2013) -

Lombard Medical Technologies PLC ("Lombard Medical" or "Company") Lombard Medical Announces Formal US Launch of AorfixTM at VEITH Symposium The Only FDA Approved Endovascular Stent Graft for Use in Challenging Abdominal Aortic Aneurysm Cases London, UK and Irvine, CA, November 18, 2013 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company focused on the treatment of abdominal aortic aneurysms (AAAs), today announces a stand-alone symposium and program of presentations to mark the formal US launch of AorfixTM, the Company's flexible stent graft, at the 40th Annual VEITH Symposium, November 19-23, New York Hilton Midtown Hotel, Manhattan, New York City. CEO of Lombard Medical Technologies, Simon Hubbert, commented:"Published clinical data suggest that up to 30% of patients present with tortuous AAA anatomy. US physicians now have access to Aorfix, a highly effective, FDA approved treatment option for such cases. VEITH Symposium is one of the most important annual gatherings of vascular surgeons from around the world and the ideal venue to formally launch Aorfix in the US." Aorfix was approved by the US FDA in February this year and includes a unique label indication for the treatment of patients with neck angulations up to and including 90 degrees. Lombard Medical will be hosting a launch stand-alone symposium, where leading physicians will present clinical data and provide their first-hand experience of Aorfix, on Thursday November 21, 12:00 noon to 1:00 PM. Clinical discussions at the launch stand-alone symposium will be led by key investigators from the Pythagoras US clinical trial of Aorfix, including: * Overall 1-year results of the Aorfix Pythagoras PMA Study - Mark F. Fillinger, M.D. Director, Vascular Surgery Training Programs, Professor of Surgery, Geisel School of Medicine, Dartmouth and Principal Investigator for Lombard's PMA Trial * Anatomical angles and effect on Aorfix PMA Study results - Mahmoud B. Malas, M.D. Chief of Endovascular Surgery and Director of Vascular and Endovascular Clinical Research, Johns Hopkins Bayview Medical Center * Gender and its impact on Aorfix PMA Study outcomes - William D. Jordan Jr., M.D. Professor of Vascular Surgery, University of Alabama School of Medicine * Access techniques for tortuous anatomy - Jeffrey P. Carpenter, M.D. Chairman and Chief, Department of Surgery, Cooper University Health Care * Clinical insights from the Aorfix PMA Study - Kim J. Hodgson, M.D. Professor and Chair, Division of Vascular Surgery, SIU School of Medicine In addition, Lombard Medical will host a meeting and product demonstration for investors and analysts on November 20, 2:30 PM to 4:30 PM at the Hilton hotel, no new material financial or other information will be disclosed. The following presentations highlighting Aorfix will also take place at this year's VEITH Symposium on Friday November 22: * Advantages and Limitations of the Lombard Aorfix Endograft. Now FDA Approved in the US - Mark F. Fillinger, M.D. Director, Vascular Surgery Training Programs, Professor of Surgery, Geisel School of Medicine, Dartmouth and Principal Investigator for Lombard's PMA Trial * Challenging Anatomy: Can Freedom from Adjunctive Fixation mean Freedom from Migration and Endoleak? - Prof. Brian R. Hopkinson, M.D., Emeritus Professor of Vascular Surgery, University of Nottingham; Consultant Vascular Surgeon, Queen's Medical Centre, Nottingham, United Kingdom -Ends- For further information: Lombard Medical Technologies PLC Tel: +44(0)1235 750 800 Simon Hubbert, Chief Executive Officer Ian Ardill, Chief Financial Officer Canaccord Genuity Limited Tel: +44(0)20 7523 8000 Lucy Tilley / Tim Redfern / Henry Fitzgerald O'Connor / Dr Julian Feneley FTI Consulting Tel: +44(0)20 7831 3113 Simon Conway / Stephanie Cuthbert / Victoria Foster Mitchell Allen & Caron Tel: +1 (949) 474 4300 Matt Clawson About VEITH Symposium Now in its fourth decade, VEITH Symposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features 430 rapid-fire presentations from world-renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. To register to attend VEITH Symposium, please visit www.VEITHpress.org . About Abdominal Aortic Aneurysms AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year 600,000 new cases are diagnosed. In the U.S. aortic aneurysm disease is among the leading cause of death and it is estimated that 1.7 million people over the age of 55 have abdominal aortic aneurysms. According to independent market research, the U.S. AAA market is estimated at more than $600 million annually and is forecast to grow to $1.6 billion worldwide by 2015. About Lombard Medical Lombard Medical Technologies PLC (AIM: LMT) is a medical device company focused on device solutions for the $1.3 billion per annum abdominal aortic aneurysm (AAA) repair market. The Company's lead product, Aorfix, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy, which is often present in advanced AAA disease. Aorfix is the only stent graft approved for AAA neck angulations of up to 90 degrees and is currently being commercialized worldwide. Aorfix is the first AAA stent graft not of U.S. origin to gain FDA approval. The Company is headquartered in Oxfordshire, England with U.S. operations in Irvine, CA. Further background on the Company can be found at www.lombardmedical.com . This information is provided by RNS The company news service from the London Stock Exchange END